RFX5 and cervical cancer: Recurrent amplification events previously unreported in cervical cancer were identified (in genomic order, frequency in percentages) at 1p31.1 (NFIA, 31%), 1q21.3 (RFX5, 51%), 4q12 (SRD5A3, 6%), 6p21.33 (GNL1, 26%), 18p11.31 (TGIF1, 18%), 19q13.13 (WDR87, 12%), 19q13.2 (NFIC, 13%), and Xq28 (HCFC1, TMEM187, 23%) (Supplementary Table 7a).